其實已有兩種提取物被使用和正在臨床試驗中:
1. Sativex®,用於緩解癌症病人疼痛,正在第三期臨床試驗中.
2. Epidiolex® ,用於治療Dravet綜合征（嬰兒嚴重肌陣攣性癲癇）.
For example, in April 2014, GW Pharmaceuticals announced that FDA granted Fast-Track designation20 to its investigational drug product Sativex®, composed primarily of two cannabinoids: CBD (cannabidiol) and THC, administered as a metered-dose oromucosal spray, for the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. Sativex is currently in Phase 3 clinical trials for this indication. In addition, on June 6, 2014, GW Pharmaceuticals announced that FDA granted Fast-Track designation to its investigational CBD product, Epidiolex®, in the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy.21
FDA---Mixed Signals: The Administration’s Policy on Marijuana—Part Four—the Health Effects and Science
American Cancer Society這一篇長文也可以參考:
Marijuana - American Cancer Society
